Effects of selected antihypertensives and analgesics on hepatic porphyrin accumulation: implications for clinical porphyria.
When patients with acute porphyrias are treated with antihypertensives and analgesics, they could be placed at increased risk of developing porphyric attacks, since little is known about the potential for many of these drugs to induce these attacks. We used primary chick embryo liver cells, which maintain intact heme synthesis and regulation, to study the effects of antihypertensives and analgesics on porphyrin accumulation. Cells were treated with desferrioxamine to block heme synthesis partially, simulating conditions encountered in porphyric patients. Typically, cells were treated for 20 hr with the test drugs (3.16 to 1000 microM), along with desferrioxamine. Porphyrins were measured spectrofluorometrically, as uro-, copro,- and protoporphyrin. The evaluated drugs included six antihypertensives (two calcium channel blockers, an angiotensin receptor antagonist, and three inhibitors of angiotensin converting enzyme) and eight analgesics. Of the calcium channel blockers tested, nifedipine greatly increased porphyrin accumulation, whereas diltiazem caused only a slight increase. Losartan (an angiotensin receptor antagonist), captopril, or lisinopril (two angiotensin converting enzyme inhibitors) produced only small increases in porphyrin accumulation. In contrast, enalapril (another angiotensin converting enzyme inhibitor) substantially increased porphyrin accumulation when given in high concentrations. Among the analgesics tested, fentanyl and tramadol produced the highest porphyrin accumulations. Nalbuphine, hydrocodone, oxycodone, and dezocine were moderately or weakly porphyrogenic, whereas buprenorphine and morphine did not increase porphyrin accumulation. These studies suggest that patients with acute porphyrias may be at greater risk for developing porphyric attacks when treated with nifedipine (compared with diltiazem), enalapril (compared with captopril or lisinopril), and tramadol (compared with the other analgesics).
Lambrecht
R W
RW
Department of Medicine, University of Massachusetts Medical School, Worcester 01655, USA. Richard.Lambrecht@BANYAN.ummed.edu
Gildemeister
O S
OS
Williams
A
A
Pepe
J A
JA
Tortorelli
K D
KD
Bonkovsky
H L
HL
D000700:Analgesics / Q000009:adverse effects / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology*; D002478:Cells, Cultured; D002642:Chick Embryo; D008099:Liver / Q000166:cytology / Q000187:drug effects; D017094:Porphyrias, Hepatic / Q000139:chemically induced* / Q000378:metabolism; D011166:Porphyrins / Q000378:metabolism*
D000700:Analgesics; D000959:Antihypertensive Agents; D011166:Porphyrins